| Paroxysmal nocturnal hemoglobinuria
Fabhalta vs Voydeya
Side-by-side clinical, coverage, and cost comparison for paroxysmal nocturnal hemoglobinuria.Deep comparison between: Fabhalta vs Voydeya with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVoydeya has a higher rate of injection site reactions vs Fabhalta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Voydeya but not Fabhalta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fabhalta
Voydeya
At A Glance
Oral
Twice daily
Factor B inhibitor
Oral
Three times daily
Complement Factor D inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- IGA Glomerulonephritis
- Complement 3 Glomerulopathies
- Paroxysmal nocturnal hemoglobinuria
Dosing
Paroxysmal nocturnal hemoglobinuria, IGA Glomerulonephritis, Complement 3 Glomerulopathies 200 mg orally twice daily without regard to food; swallow capsules whole.
PNH Patients Switching From Anti-C5 Initiate FABHALTA no later than 1 week after last eculizumab dose or no later than 6 weeks after last ravulizumab dose.
Paroxysmal nocturnal hemoglobinuria 150 mg orally three times a day as starting dose; may increase to 200 mg three times a day if hemoglobin has not increased by >2 g/dL after 4 weeks, if transfusion was required in the previous 4 weeks, or based on clinical judgment.
Contraindications
- Serious hypersensitivity to iptacopan or any of the excipients
- Unresolved serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type b (contraindicated for initiation)
- Unresolved serious infection caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, or Haemophilus influenzae type B
Adverse Reactions
Most common (>=10%) headache, nasopharyngitis, diarrhea, abdominal pain, bacterial infection, viral infection, nausea, rash
Serious serious infections caused by encapsulated bacteria, hyperlipidemia
Most common (>=10%) Headache
Serious Pancreatitis, cholecystitis, blood bilirubin increased
Pharmacology
Factor B inhibitor; iptacopan binds to Factor B of the alternative complement pathway, regulating C3 cleavage and inhibiting downstream effectors to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis in PNH, and to inhibit complement-driven glomerular injury in IgAN and C3G.
Complement Factor D inhibitor; danicopan binds reversibly to Factor D and selectively inhibits the alternative complement pathway, preventing C3 convertase formation, reducing C3 fragment opsonization, and thereby controlling extravascular hemolysis in PNH when used as add-on therapy to a terminal complement inhibitor.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fabhalta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Voydeya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Fabhalta
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Voydeya
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Fabhalta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Voydeya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Immunoglobulin A Nephropathy (IgAN)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Alexion OneSourceCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FabhaltaView full Fabhalta profile
VoydeyaView full Voydeya profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.